title: Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.
abstract: [(68)Ga]-DO3A-VS-Cys(40)-Exendin-4 has been shown to be a promising imaging candidate for targeting glucagon like peptide-1 receptor (GLP-1R). In the light of radiotheranostics and personalized medicine the (177)Lu-labelled analogue is of paramount interest. In this study we have investigated the organ distribution of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 in rat and calculated human dosimetry parameters in order to estimate the maximal acceptable administered radioactivity, and thus potential applicability of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 for internal radiotherapy of insulinomas. Nine male and nine female Lewis rats were injected with [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 for ex vivo organ distribution study at nine time points. The estimation of human organ/total body absorbed and total effective doses was performed using Organ Level Internal Dose Assessment Code software (OLINDA/EXM 1.1). Six more rats (male: n = 3; female: n = 3) were scanned by single photon emission tomography and computed tomography (SPECT-CT). The renal function and potential cell dysfunction were monitored by creatinine ISTAT and glucose levels. The fine uptake structure of kidney and pancreas was investigated by ex vivo autoradiography. Blood clearance and washout from most of the organs was fast. The kidney was the dose-limiting organ with absorbed dose of 5.88 and 6.04 mGy/MBq, respectively for female and male. Pancreatic beta cells demonstrated radioactivity accumulation. Renal function and beta cell function remained unaffected by radiation. The absorbed dose of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 to kidneys may limit the clinical application of the agent. However, hypothetically, kidney protection and peptidase inhibition may allow reduction of kidney absorbed dose and amplification of tumour absorbed doses.
authors.affiliation: Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University SE-75183 Uppsala, Sweden ; PET-Centre, Centre for Medical Imaging, Uppsala University Hospital Uppsala, Sweden ; Department of Radiology, Oncology, and Radiation Science, Uppsala University SE-75285 Uppsala, Sweden.
authors.forename: Irina
authors.initials: I
authors.lastname: Velikyan
authors.affiliation: Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University SE-75183 Uppsala, Sweden.
authors.forename: Thomas N
authors.initials: TN
authors.lastname: Bulenga
authors.affiliation: Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University SE-75183 Uppsala, Sweden.
authors.forename: Ramkumar
authors.initials: R
authors.lastname: Selvaraju
authors.affiliation: PET-Centre, Centre for Medical Imaging, Uppsala University Hospital Uppsala, Sweden ; Department of Radiology, Oncology, and Radiation Science, Uppsala University SE-75285 Uppsala, Sweden.
authors.forename: Mark
authors.initials: M
authors.lastname: Lubberink
authors.affiliation: Department of Medical Cell Biology, Uppsala University SE-75285 Uppsala, Sweden.
authors.forename: Daniel
authors.initials: D
authors.lastname: Espes
authors.affiliation: Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University SE-75183 Uppsala, Sweden.
authors.forename: Ulrika
authors.initials: U
authors.lastname: Rosenström
authors.affiliation: Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University SE-75183 Uppsala, Sweden.
authors.forename: Olof
authors.initials: O
authors.lastname: Eriksson
keywords: Exendin-4; Lu-177; dosimetry; imaging; insulinoma; radiotherapy